A phase 1b study of ETX-155 in patients with photosensitive epilepsy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Oct 2022 Status changed from suspended to discontinued, according to an Eliem Therapeutics media release.
05 Oct 2022 According to an Eliem Therapeutics media release, the company has determined it will not reinitiate the PSE proof-of-concept trial but will continue to pursue development of ETX-155 in focal onset seizures (FOS).
18 Jul 2022 Status changed from recruiting to suspended, according to an Eliem Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com